Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
109
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma

Farheen Manjia Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]
View further author information
,
Sita Bhellaa Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaView further author information
,
Robert Kridela Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaView further author information
,
Vishal Kukretia Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaView further author information
,
John Kuruvillaa Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-6117-320XView further author information
ORCID Icon,
Anca Pricaa Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaView further author information
&
Michael Crumpa Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;b Department of Medicine, University of Toronto, Toronto, ON, CanadaView further author information
 show all
Pages 3402-3408 | Received 25 Jun 2022, Accepted 01 Sep 2022, Published online: 27 Sep 2022

References

  • Flinn IW, Van Der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet. 2013;381(9873):1203–1210.
  • Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
  • Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–4586.
  • Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314–320.
  • Morschhauser F, Fowler NH, Feugier P, RELEVANCE Trial Investigators, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947.
  • Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
  • Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the groupe d‘Etudes des lymphomes de l‘Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317–4322.
  • Trotman J, Fournier M, Lamy T, et al. Positron emission tomography–computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194–3200.
  • Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95(1):11–18.
  • Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma. CMAR. 2019;11:6871–6885.
  • Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761–764.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.